{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 12 of 92', 'CR845-CLIN3102', 'The Per-Protocol Population is defined as the subset of patients in the', 'ITT who do not have any major protocol deviations that could affect', 'the efficacy analyses of the double-blind data.', 'Inclusion in the Per-Protocol Population will be determined prior to', 'unblinding the data and will be detailed in the statistical analysis plan.', 'The Open-label Safety Population is defined as the group of patients', 'who receive at least 1 dose of study drug in the Open-label Phase. The', 'Open-label Safety Population will be used to analyze all safety', 'endpoints collected during the Open-label Phase, and during exposure', 'to CR845 combining data from both the Double-blind and the', 'Open-label Phases.', 'Safety Analyses', 'Safety data will be summarized descriptively. No inferential statistics', 'are planned. Analyses of safety data will include summaries of', 'treatment-emergent adverse events including Adverse Events of', 'Special Interest (AESI), serious adverse events, and adverse events', 'resulting in study drug discontinuation. Vital signs, chemistry and', 'hematology data, ECG data will be presented by visit as applicable, in', 'addition to change from baseline.', 'Efficacy Analyses (Double-blind Treatment Period)', 'All efficacy analyses will be conducted on the ITT Population. An', 'analysis of the primary and secondary efficacy variables for the Per-', 'Protocol Population will also be performed.', 'Primary Efficacy Enppoint', 'The primary efficacy endpoint is defined as the proportion of patients', 'achieving at least a 3-point improvement from baseline with respect to', 'the weekly mean of the daily 24-hour Worst Itching Intensity NRS', 'score at Week 12 (Days 79-85) of the Double-blind Treatment Period.', 'The weekly mean of the 24-hour Worst Itching Intensity NRS score', 'will be defined as the sum of the daily Worst Itching Intensity NRS', 'score reported during a specific week during the Double-blind', 'Treatment Period (eg, Days 2 to 8, Days 9 to 15, Days 16 to 22, etc,.', 'Days 79 to 85) divided by the number of days with non-missing scores', 'for that week. If the daily worst itching score is missing for >3 days', 'during a specific week, the corresponding weekly mean worst itching', 'score will be set to missing. The baseline score will be defined as the', 'average of the daily 24-hour Worst Itching Intensity NRS scores', 'collected over the Run-in Period, including pre-randomization', 'assessments collected on Day 1.', 'In the primary efficacy analysis, missing NRS data will be imputed', 'using a multiple imputation (MI) approach, assuming that patients who', 'discontinue double-blind treatment early would have similar Worst', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 14 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 13 of 92', 'CR845-CLIN3102', 'Itching Intensity NRS scores as other patients in their respective', 'treatment arm that have complete data:', 'Intermittent missing NRS scores will first be imputed using the', 'Markov Chain Monte Carlo (MCMC) method implemented with', 'the SAS MI procedure, which is appropriate for non-monotonic', 'missing data.', 'NRS scores missing after patients discontinue study drug early will', 'then be multiply imputed with the SAS MI procedure using a', 'method appropriate for monotone missingness (eg, regression', 'statement).', 'The proportion of patients who have an improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS score 3 points will be calculated for', 'each imputed dataset. Differences between CR845 0.5 mcg/kg and', 'placebo with respect to the primary endpoint will be compared', 'using a logistic regression model containing terms for treatment', 'group, baseline NRS score, use of prior anti-itch medication, and', 'presence of specific medical conditions', 'Results of the logistic regression on the multiply imputed data sets', 'will be summarized by the SAS MIANALYZE procedure.', 'Sensitivity analyses of the primary efficacy endpoint will be conducted', 'to evaluate the robustness of study results under different assumptions', 'and imputation algorithms (Section 8.7.1).', 'Secondary Efficacy Enpoints', 'The Skindex-10 Scale total score and the 5-D Itch Scale total score will', 'be analyzed using a mixed effects model with repeated measures', '(MMRM) that will contain treatment, week, and treatment-by-week', 'interaction as fixed effects; baseline score, prior anti-itch medication', 'usage and presence of specific medical conditions as covariates; and', 'patient as a random effect. Repeated measures will include values', 'collected at the end of Weeks 4, 8, 10, and 12 (end of treatment). The', 'mean treatment difference between CR845 0.5 mcg/kg and placebo', 'will be estimated as the simple contrast in the treatment effect at', 'Double-blind Treatment Period Week 12.', 'It is important to note that, in HD patients, the study drug administered', 'during the last dialysis of a particular week is not cleared until the first', 'dialysis of the next week. Therefore, measurements that would reflect', 'treatment effect at the end of a specific week (eg. Week 4) will actually', 'be collected during the first day of the next week (eg. Week 5).', 'The proportion of patients achieving >4-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour Worst', 'Itching Intensity NRS at Week 12 of the Double-blind Treatment', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 15 of 95']\n\n###\n\n", "completion": "END"}